Co-Diagnostics Joint Venture, CoSara, Invited to Participate in 2nd Advanced TB Diagnostics Course in Chennai, India
Collaboration expands Owlet’s national DME footprint, strengthens access for Medicaid and TRICARE families, and supports continued growth in prescription-backed revenue channel.
In-vitro studies confirmed strong uptake of cell-targeting nanoparticles by cancer cells and strong activation of Smart mRNAs inside cancer cells
Peel Therapeutics CEO Joshua Schiffman Presents at CureCRC Summit
Ratio Therapeutics has Successfully Dosed the First Cohort in its Phase 1/2 Study Evaluating a Novel FAP-Targeted Radiopharmaceutical in Patients with Late-Stage Aggressive Sarcomas
Investors Buy up Stocks in Biggest Follow-on Offering Day in Biotech History
Talent Ready Utah Calling for Innovator Input
TGA approval enables regional launch of Owlet’s clinically validated, award-winning infant health monitor; Owlet360™ subscription marks first international expansion of the Company’s recurring-revenue platform.
REC-4881 (4 mg QD) achieved rapid clinical activity, with 75% of evaluable patients showing reductions in total polyp burden and a 43% median reduction after 12 weeks of treatment (n=12).
New findings demonstrate a 72% HI-E response rate at Week 16 with meaningful hemoglobin improvement.
FDA recommended biomarker analyses show statistically significant reductions in NfL and GFAP in participants treated with CNM-Au8.
Prestigious recognition validates Canary Speech’s leadership in healthcare-focused AI voice technology and its proven interoperability with the Microsoft Cloud